PUBLIC COMPANY
saveAIkido Labs Inc
10 employees · New York, NY, USupdated 1mo ago
AIkido Labs Inc is a biotechnology subsidiary of Dominari Holdings (Nasdaq: DOMH) developing a portfolio of early and mid-stage small-molecule anti-cancer therapeutics for prostate cancer, pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. Its pipeline includes DHA-dFdC (licensed from the University of Texas at Austin) for pancreatic cancer and KPC34 (from Wake Forest University) for AML/ALL. The company also holds a worldwide license to a broad-spectrum antiviral platform from the University of Maryland Baltimore.
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Preclinical
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
no news has mentioned this company yet
comments(0)
5-min edit window · permanent after that